Study: Could the Same Radio Waves From Your Phone Help…

This is part of our Study Spotlight series, where we break down the latest peer-reviewed EMF research into plain language. No hype, no dismissal — just what the science actually says.

Here’s a plot twist most people don’t see coming: the same radiofrequency electromagnetic fields (RF-EMFs) that fuel health anxiety about cell phones and WiFi routers might actually help treat one of the most devastating diseases in medicine.

A comprehensive review published in Electromagnetic Biology and Medicine in February 2026 examined the accumulating evidence that RF-EMF exposure — at frequencies and intensities similar to those from everyday wireless devices — may slow or even reverse aspects of Alzheimer’s disease.

The review covers studies at every level: cells in dishes, living animals, and early-stage human trials. And the findings are surprisingly consistent.

Why Would Anyone Try Treating Alzheimer’s With Radio Waves?

Alzheimer’s disease (AD) is defined by two pathological hallmarks: amyloid-beta (Aβ) plaques that build up between brain cells, and neurofibrillary tangles of tau protein inside them. Together, they destroy neurons, erase memories, and rob patients of independence.

Current drug treatments are limited to managing symptoms. Nothing reliably stops the disease. That’s driven researchers to explore unconventional approaches — including electromagnetic fields.

The idea isn’t as far-fetched as it sounds. RF-EMFs penetrate the skull and interact with brain tissue. If that interaction could be directed productively — clearing plaques, boosting metabolism, reducing inflammation — it would represent a completely new class of treatment. One that requires no injection, no surgery, and no swallowing pills.

What the Cell and Molecular Studies Found

At the cellular level, multiple studies have shown that RF-EMF exposure can:

Reduce amyloid-beta production by modulating the expression of genes involved in Aβ secretion — the enzymes (β-secretase and γ-secretase) that cleave the amyloid precursor protein into toxic fragments
Activate autophagy pathways — the cell’s built-in garbage collection system — specifically chaperone-mediated autophagy, which helps clear damaged proteins
Enhance mitochondrial function — mitochondria are the cell’s power plants, and their decline is a key feature of Alzheimer’s

These aren’t fringe observations from a single lab. The review documents findings across multiple research groups using different cell types and exposure conditions.

Check your EMF exposure

See cell towers, power lines, and substations near any US address.

Search Your Address

The Animal Evidence: Memory Improvement in AD Mice

The animal studies are where things get especially interesting. Transgenic mice engineered to develop Alzheimer’s-like pathology have been a workhorse model for testing potential therapies. When exposed to RF-EMFs:

Brain Aβ deposition decreased — the hallmark plaques that define the disease were physically reduced
Cerebral glucose metabolism improved — brain cells were taking up and using energy more efficiently, reversing a key metabolic deficit seen in AD
Memory and cognitive function improved — mice performed better on standard maze and recognition tasks after RF-EMF exposure
Inflammatory responses were modulated — the chronic neuroinflammation that accelerates neurodegeneration was dialed down

These weren’t one-off findings. The review traces a consistent pattern across multiple animal studies, many using 918 MHz exposure (close to common cellular frequencies) over periods of weeks to months.

Early Human Evidence

The most provocative part of the review addresses early clinical studies. While still limited, initial human trials have explored whether transcranial electromagnetic treatment (TEMT) — essentially targeted RF exposure to the brain — can benefit Alzheimer’s patients.

Early results, though from small cohorts, have shown trends toward:

Improved cognitive scores on standardized tests
Enhanced brain metabolism visible on PET scans
No significant adverse effects from the treatment

The review is careful to note these are preliminary results that need larger, controlled trials. But the direction of the evidence is notable: no harm observed, potential benefit detected.

What This Means for the EMF Health Debate

This is where the study gets genuinely important for anyone worried about everyday EMF exposure.

The core finding is this: at frequencies and power levels in the range of everyday wireless devices, RF-EMFs appear to have beneficial biological effects on brain tissue — at least in the context of Alzheimer’s pathology.

This doesn’t mean your phone is treating your brain. The therapeutic studies use controlled, specific exposure protocols. But it does challenge the simplistic narrative that “RF radiation = brain damage.” If RF-EMFs were purely destructive to brain tissue, you wouldn’t expect to see consistent neuroprotective effects across multiple studies and research groups.

The review also highlights that the mechanisms at work — enhanced autophagy, improved mitochondrial function, modulated inflammation — are the same pathways that many pharmaceutical companies are spending billions trying to target with drugs. RF-EMFs may activate them non-invasively.

Limitations Worth Noting

This is a narrative review, not a meta-analysis — it synthesizes available evidence but doesn’t statistically pool results. Other important caveats:

Animal models aren’t humans — transgenic AD mice are useful but don’t perfectly replicate the human disease
Dose-response details are incomplete — the optimal frequency, power level, exposure duration, and treatment window remain unclear
Long-term effects unknown — beneficial short-term results don’t guarantee safety or efficacy over years
Small human samples — clinical evidence remains preliminary and needs much larger trials
Publication bias possible — positive results are more likely to be published than null findings

The review’s authors are transparent about these gaps, calling for “well-designed clinical trials with larger sample sizes” to confirm the therapeutic potential.

The Bottom Line

A comprehensive 2026 review of RF-EMF research in Alzheimer’s disease found a surprisingly consistent pattern: radio-wave exposure at everyday wireless frequencies appears to reduce brain plaque, improve cellular energy use, calm neuroinflammation, and enhance memory in animal models — with early human studies pointing in the same direction.

The same type of electromagnetic fields that generate health anxiety when they come from cell towers and routers are being actively investigated as a treatment for one of medicine’s most intractable diseases.

That doesn’t mean EMF exposure is harmless in all contexts. But it does add important nuance to the conversation: the relationship between RF-EMFs and brain health is more complex — and potentially more positive — than the “radiation is dangerous” narrative suggests.

Study: Liu W, Rao X, Sun W, Chen X, Yu L, Zhang J. “Radiofrequency electromagnetic fields in Alzheimer’s therapy: emerging evidence and future prospects.” Electromagnetic Biology and Medicine, February 2026. PubMed

Frequently Asked Questions

Can my phone treat Alzheimer’s disease? No. The therapeutic studies use controlled, targeted exposure protocols — not the irregular, low-level emissions from a phone held to your ear. But the research does suggest that the type of energy emitted by phones has neuroprotective properties under certain conditions.

Does this mean EMF exposure is good for your brain? It means the relationship is more complex than “all bad.” At specific frequencies and exposures, RF-EMFs appear to activate beneficial cellular processes in brain tissue, at least in disease models. Whether this applies to healthy brains or everyday exposure levels requires more research.

What frequencies were studied? Most animal studies used frequencies around 918 MHz — within the range of common cellular communications. Some studies also explored other frequencies. The review notes that optimal parameters haven’t been established.

Is this treatment available now? Not as a standard clinical therapy. Transcranial electromagnetic treatment (TEMT) devices are in early clinical trials but haven’t received regulatory approval for Alzheimer’s treatment. This is still very much at the research stage.

How does this relate to the WHO’s classification of RF-EMFs as “possibly carcinogenic”? The WHO’s Group 2B classification is based on a different body of evidence (cancer epidemiology). The Alzheimer’s research examines different biological endpoints and finds beneficial effects. Both can be true — the same agent can have different effects on different biological processes at different exposures.